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ABSTRACT 
  
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
cannabis is effective in reducing muscle spasticity and body pain amongst patients with Multiple 
Sclerosis (MS).   
  
STUDY DESIGN: A systematic review of three peer-reviewed studies published between the 
years of 2003 and 2012.  
  
DATA SOURCES: Three randomized control trials (RCTs) evaluating if cannabis can reduce 
muscle spasticity and body pain for patients diagnosed with Multiple Sclerosis. All three sources 
were selected from PubMed and examined for outcomes that were patient oriented. 
  
OUTCOMES MEASURED: The two primary outcomes measured include: muscle spasticity 
measured by the Ashworth scale, and the patient’s perception of body pain measured by a 
subjective Category Rating Scale (CRS). 
  
RESULTS: The study conducted by Bloom et al.7 showed a significant reduction in muscle 
spasticity by an average of 2.74 points more than the placebo group on the Ashworth scale. 
Furthermore, the treatment reduced body pain by an average of 5.28 points more than the 
placebo group when assessed on a Visual Analogue CRS. The MUSEC trial conducted by 
Zajicek et al8 showed the relief from muscle stiffness after 12 weeks was almost twice as high 
with cannabis extract than with placebo (29.4% vs 15.7%; OR 2.26; 95% CI 1.24 to 4.13; 
p=0.004, one sided). Patient-reported body pain was also improved. The CAMS study conducted 
by Zajieck et al9 found that treatment with cannabinoids did not have a beneficial effect on 
spasticity when assessed with the Ashworth scale, but did find subjective improvement in 
spasticity and pain via CRSs and asking patients direct questions about their overall opinion of 
symptom improvement.  
  
CONCLUSIONS: The result of three RCTs reveals conflicting evidence in regards to muscle 
spasticity assessed by the Ashworth scale. However, clinically significant improvements of 
patient-reported muscle spasticity and pain were recorded via use of CRSs in each trial. Due to 
the limitations of these studies, further research is warranted. 
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INTRODUCTION  
 Multiple Sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the 
Central Nervous System (CNS). The destruction of myelin impairs signal transmission within the 
CNS and results in areas that develop scar tissue, resulting in a variety of symptoms. Some of the 
most notable symptoms of this disease include: blurred vision, extreme fatigue, numbness, loss 
of coordination, spasticity, and body pain. There are three distinct types of MS, however, the 
most common type of MS follows a relapsing-remitting disease course. This is characterized by 
clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial 
or complete recovery.1 This paper evaluates three Randomized Control Trials (RCTs) that 
analyze the efficacy of cannabis as treatment for improving muscle spasticity and body pain for 
patients with MS.  
 MS currently affects more than 1 million individuals in the United States. and 2.3 million 
globally. In the southern U.S., the prevalence rate is 57-78 cases per 100,000 versus 110-140 
cases per 100,000 in the northern U.S.2 These statistics suggest that geographic location may be a 
risk factor for the development of MS. Since healthcare providers are not required to report 
patients diagnosed with MS, there is no definitive method to track how many patients have 
developed this disease.  
Healthcare costs are difficult to estimate and a are largely dependent upon the type and 
severity of the patient’s symptoms. When specifically assessing the most common type of MS, 
relapsing-remitting, it is estimated to cost a patient approximately $65,000 per year and $4.1 
million dollars over the course of a lifetime. In addition, data shows that patient’s average 20 
healthcare visits per year depending on the severity of their symptoms.3 
  
The exact cause of MS is unknown, and it is unclear as to why it develops in some people 
and not others. Although genetic and environmental factors are thought to play a role, the disease 
is not contagious or inherited. The average age of onset is 20-50 years old and is at least two 
times more common in women than men.4 MS initially manifests as a Clinically Isolated 
Syndrome (CIS), which is an episode of neurologic symptoms caused by inflammation and 
demyelination of nerve fibers in the CNS. Patients may present complaining of fatigue, gait 
abnormalities, numbness/tingling, optic neuritis, pain, spasticity, and/or weakness. The diagnosis 
of MS is initially made clinically with a history of at least two discrete episodes of symptomatic 
exacerbations. Clinicians may confirm their suspicions of an MS diagnosis by ordering an MRI 
with gadolinium, which will reveal white matter plaques in the brain. In addition, a diagnosis of 
MS can also be supported via lumbar puncture to evaluate for the presence of oligoclonal bands 
and increased IgG production. Once a diagnosis of MS is made a patient will be further 
categorized as having 1 of 3 subtypes. These include: relapsing-remitting, primary progressive, 
or secondary progressive. 1 
Treatment for MS varies amongst patients. Typically, the first line medication for acute 
exacerbations are high dose IV corticosteroids. If patients are not responsive to corticosteroids, 
then plasmapheresis can be considered as a 2nd line treatment option.5 In regard to daily 
maintenance therapy, the first line treatment is β-interferon. If this medication is not adequately 
controlling the amount and severity of symptomatic relapses, then treatment with glatiramer 
acetate is indicated. Adjunct medications include amantadine for fatigue and diazepam for 
spasticity.6 Although these medications are useful in the treatment of MS, they are associated 
with a heavy cost burden and the potential for adverse side effects. 
 
  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not cannabis is 
effective in reducing muscle spasticity and body pain amongst patients with multiple sclerosis.  
 
METHODS 
 The studies were evaluated and selected based on their adherence to specific criteria:  
population studied, intervention used, comparison group, and outcomes measured. The studies 
selected for this review needed to focus on patients 18 years or older that had a confirmed 
diagnosis of MS. The intervention had to be cannabis, either smoked or oral administration. 
Comparison groups using a placebo drug were preferentially selected for this review. The 
outcomes measured needed to be patient-oriented evidence that matters (POEMs), which 
included improvement in spasticity and body pain using both objective and subjective rating 
scales. Each study used in this systematic review were RCTs comparing the effects of cannabis 
to a controlled, placebo group. Two of the three studies were double-blind RCTs.  
 PubMed was used to find RCTs published in peer-reviewed journals in the English 
language. They keywords “multiple sclerosis”, “cannabis”, “pain”, and “spasticity” were used 
when searching for these articles. Selection of each article was based on relevance to the clinical 
question, date of publication, generalizability, and outcomes that were patient oriented (POEMs). 
Inclusion criteria for all three studies included articles that were peer-reviewed RCTs and 
POEMs. Exclusion criteria were patients under the age of 18, disease-oriented evidence, and 
preexisting Cochrane systematic reviews.  The reported statistics included p-value, mean change 
from baseline, and confidence intervals. Table 1 shows the demographics and characteristics of 
included studies that were selected for this review.  
  
Table 1 - Demographics & Characteristics of included studies 
 
 
 
Study  Type  # 
Pts 
Age (yrs) Inclusion Criteria Exclusion Criteria W/D Intervention 
Corey 
Bloom7 
(2012) 
RCT 37 Avergae: 
50 years 
old  
Patients who 
were 18 years or 
older with MS  
Patients with a history of 
major psychiatric disorder 
(other than depression), 
substance abuse, 
neurologic disease (other 
than MS), unstable 
medical illness, pregnant 
and breastfeeding women  
7 Smoked 
cannabis 
cigarettes (4% 
delta-9-THC) 
VS. Placebo 
identical 
cigarette. After 
an 11-day 
washout 
interval, 
participants 
crossed over to 
the opposite 
group.  
Zajicek8 
(2012) 
 
RCT 279 18-64 Patients with 
stable MS for the 
past 6 months, 
who have 
ongoing muscle 
stiffness for at 
least 3 months 
before 
enrollment 
Patients with active 
sources of infection or 
taking immunomodulatory 
drugs that might affect 
spasticity, fixed tendon 
contractures, severe 
cognitive impairment, 
major illness, pregnancy, 
cannabis use in the past 30 
days, history of psychosis 
53 Oral cannabis 
extract (titrated 
over 2 weeks to 
reach a 
maximum dose 
of 25mg daily) 
VS. placebo. 
Duration of 
treatment was 
12 weeks. 
Patients were 
assessed at 
2,4,8, and 12 
weeks 
Zajicek9 
(2003) 
RCT 667 18-64 Patients with 
clinically definite 
or laboratory-
supported MS. 
Disease must 
have been stable 
for the previous 6 
months with 
problematic 
spasticity.  
Ischemic heart disease, 
patients > 64 years old, 
active infection, severe 
cognitive impairment , 
pregnancy, use of cannabis 
in the 30 days prior to the 
start of the study, past 
history of psychotic 
illness, patients taking 
immunomodulator drugs 
that may affect spasticity, 
fixed tendon contractures 
56 Oral Cannabis 
extract & delta-
9-THC VS. 
Placebo. 
Duration of trial 
was 15 weeks  
  
OUTCOMES MEASURED 
The outcomes measured were patient oriented (POEMs) and assessed by similar methods 
across each study. Bloom et al.7 assessed muscle spasticity via the modified Ashworth rating 
scale. Investigators combined ratings for both elbows, hips and knees for a total possible score of 
30 points. Participants were assessed using this scale before and approximately 45 minutes after 
treatment (cannabis or placebo) at each visit. In order to assess perceived pain, investigators 
administered a subjective visual analogue scale to their participants.7 
In the MUSEC trial, Zajiek et al.8 measured both muscle spasticity and body pain with 
subjective category rating scales (CRS). Muscle spasticity was measured with an 11-point CRS 
to evaluate perceived change in muscle stiffness after 12 weeks of treatment compared with the 
premedication phase. At the final visit, participants answered the following question on a 
symptom questionnaire: “Compared with before the study started, my muscle stiffness over the 
last week has been…” providing a rating on an 11-point numerical CRS where 0 = 
very much better, 5= no difference, and 10= very much worse. Ratings of 0-3 on the rating scale 
were classified as a clinically relevant response.8 Body pain was also measured on a CRS at 4, 8, 
and 12 weeks. Participants would answer the question, “Over the last week, the body pain I have 
had is…” providing a rating in categories between “no body pain and “extreme body pain”.8 
 The CAMS study, also conducted by Zajiek et al.9 measured muscle spasticity with the 
Ashworth rating scale. Assessments were made at six visits: two pre-treatment (visits 1 and 2), 
three while on treatment (visits 5, 6, and 7), and one after discontinuation of treatment (visit 8). 
At each visit, 10 muscle groups were evaluated on each side of the body while participants were 
lying supine on a couch (or as close to this position as was tolerated) after resting for 15 minutes. 
CRSs were also used in this study to subjectively measure muscle spasticity and pain. They were 
  
administered at the end of the treatment phase only. Participants were asked to assess their 
symptoms over the previous week and compare them with how they were just before the study 
began. At the end of the 15 weeks, the treating doctor asked the participants specific questions 
about the overall effect of the medication on spasticity and pain (visit 8). 9  
RESULTS 
This review consists of three RCTs that assessed whether cannabis is an effective 
treatment for reducing muscle spasticity and body pain amongst patient with MS. Each trial 
presented their outcomes as continuous data.  
 In the study conducted by Bloom et al.7, 196 patients were recruited for screening from a 
regional MS clinic and by referral from specialists. Inclusion criteria included patients greater 
than 18 years old and a baseline Ashworth score of at least 3 points. Patients were excluded if 
they had a history of a major psychiatric disorder (other than depression), substance abuse, 
neurologic disease (other than MS), pregnant or breastfeeding women, or an unstable medical 
illness.7 Of the 196 patients recruited, 37 were randomized into either a smoked cannabis or 
placebo group. Pre-rolled cannabis and placebo cigarettes were identical in appearance and 
weight. Cannabis cigarettes contained 4% delta-9-tetrahydrocannabinol (delta-9-THC) by weight 
while placebo cigarettes contained the same material with delta-9-THC removed.7 The Ashworth 
scale was used to evaluate muscle spasticity and a visual analogue scale was administered to 
evaluate body pain. By the end of the trial, 7 patients withdrew due to adverse side effects (n=4) 
or unavailability for time commitment (n=3).7 
Results show that smoking cannabis reduced Ashworth scale scores by an average of 2.95 
points from baseline, which was 2.74 points more than placebo group (95% CI 2.20 to 3.14). P-
value was calculated to be < 0.001. Smoking cannabis reduced patient scores on the visual 
  
analogue scale by an average of 8.27 points from baseline, which was 5.28 points more than 
placebo (95% CI 2.48 to 10.01). The calculated p-value for this scale was 0.008.7 Overall, this 
trial showed a large and beneficial effect of smoked cannabis on spasticity and pain associated 
with MS.  
Although smoked cannabis was well-tolerated adverse effects were noted. These 
included: dizziness, headache, fatigue, nausea, throat irritation, and feeling “too high”. As 
mentioned previously, 4 patients withdrew from the trial due to intolerable side effects. 
However, none of the participants experienced episodes of hypertension, hypotension, 
tachycardia, or bradycardia that required medical intervention.  
Table 2: Efficacy of smoked cannabis on muscle spasticity and body pain measured by the 
Ashworth Scale and Visual Analogue Scale conducted by Bloom et al.7   
Study: Bloom et. al 7   Mean Change from 
Baseline  
CI (95%) P-value 
Smoked cannabis: 
spasticity (Ashworth 
Scale) 
-2.95 2.20 – 3.14 <0.001 
Smoked Cannabis: 
body pain (Visual 
Analogue Scale) 
-8.27 2.48 – 10.01 0.008 
 
 In 2012, Zajicek et al.8 conducted the MUSEC trial with a sample size of 279 patients. 
Patients ranged from 18-64 years old and were required to have a diagnosis of MS according to 
the McDonald Criteria. In addition, their disease had to have been stable for the previous 6 
months with ongoing muscle stiffness for at least 3 months before the trial began.8 Exclusion 
  
criteria included patients with active sources of infection or taking immunomodulatory drugs that 
might affect spasticity, fixed tendon contractures, severe cognitive impairment, major illness, 
pregnancy, cannabis use in the past 30 days, or history of psychosis.8 
 Patients were randomized to either an oral cannabis extract or placebo group via a 
computer-generated voice response system. Both study groups received identical oral capsules 
and all investigators and participants were blinded to treatment distribution throughout the trial. 
The starting dose was 2.5mg of delta-9-tetrahydrocannabinol (Δ9THC) twice daily. Patients were 
titrated up by 5mg every 3 days until a maximum dose of 25mg Δ9THC was achieved.8 
 Investigators administered CRSs to assess muscle spasticity and body pain. Results show 
that the proportion of participants experiencing muscle relief after 12 weeks of oral cannabis was 
nearly 2x higher than the placebo group (29.4% vs 15.7%; OR 2.26; 95% CI 1.24 to 4.13; 
p=0.004, one sided). The mean reduction of muscle stiffness from baseline = -1.8 ±2.6.8 This 
indicates a large treatment effect. Similar results were found when evaluating body pain. After 
12 weeks, 28% of patients allocated to the cannabis extract group reported decreased body pain 
as compared to 18.7% of patients in the placebo group (p=0.028). The mean reduction of body 
pain from baseline = -1.2 ± 2.6 . This indicates a large treatment effect.8  
 Adverse events were most notable during the upward titration phase of Δ9THC. In the 
cannabis extract group, 46.2% of patients experienced dizziness vs. only 6.7% in the placebo 
group. In addition, 14% of cannabis patients reported feeling fatigued in comparison to only 6% 
of placebo patients. Of the 279 patients randomized, 39 withdrew due to adverse events.8 
Although side effects were noted, they were consistent with the known effects of cannabinoids. 
No new safety concerns were detected, and the study achieved its goal to demonstrate the 
usefulness of oral cannabis extract to treat muscle spasticity and body pain in patient with MS.  
  
Table 3: Efficacy of oral cannabis extract on muscle spasticity and body pain measured by 
Category Rating Scales conducted by Zajicek et al.8   
Study: Zajieck et. al 8   Mean change from baseline 
(Mean change ± SD) 
P-value 
Oral cannabis: spasticity  -1.8 ±2.6 0.004 
Oral cannabis: body pain -1.2 ± 2.6    0.028 
 
 The CAMS study conducted by Zajieck et al.9 enrolled 667 patients with MS. Of these 
patients, 630 of them were randomized into one of the following groups: oral cannabis extract 
(n=211), Δ9THC (n=206), or placebo (n=213). 9 Eligible patients were those between the age of 
18-64 years old, clinically definite or laboratory-supported MS, and stable disease state for the 
previous 6 months with problematic spasticity. Exclusion criteria included: ischemic heart 
disease, active infection, severe cognitive impairment, pregnancy, use of cannabis in the 30 days 
prior to the start of the study, history of psychotic illness, patients taking immunomodulator 
drugs that may affect spasticity, and fixed tendon contractures. Throughout the duration of the 
study 56 patients withdrew, leaving 611 to be assessed for efficacy and outcome measurements 
over the next 10 weeks. 9 
 Compared to baseline assessments, results show a mean reduction in total Ashworth 
score for patients taking oral cannabis extract vs. placebo to be 0.32 (95% CI -1.04 to 1.67; 
p=0.40). For those patients taking Δ9THC vs. placebo the mean reduction in total Ashworth 
score was 0.94 (95% CI -0.44 to 2.31). 9 The results of the Ashworth scale indicate that 
cannabinoids did not have a clinically significant effect on reducing muscle spasticity. However, 
there was evidence of treatment effect on patient-reported spasticity and pain measured by an 11-
point CRS. Improvement of spasticity was recorded in 61% of patients on cannabis extract 
  
(n=121, 95% CI 54.6 – 68), 60% of patients receiving Δ9THC (n=108, 95% CI 52.5 – 66.8), and 
46% of patients in the placebo group (n=91, 95% CI 39.0 - 52.90). In regard to body pain, 
reductions were seen in 57%, 50%, and 37% of participants on cannabis extract, Δ9THC, and 
placebo respectively. 9 Episodes of adverse events were most commonly seen in the active 
treatment groups and were consistent with the known side effects of cannabinoids. These 
included: dizziness, lightheadedness, increased appetite, dry mouth, urinary tract infection, and 
diarrhea. 9  
  Table 4: Efficacy of oral cannabis extract and Δ9THC on muscle spasticity 
measured by Ashworth scale conducted by Zajicek et al.9   
Study: Zajieck et. al 9   Mean change from baseline CI 
Oral cannabis extract vs. 
placebo- spasticity (Ashworth 
scale) 
0.32 -1.04 to 1.67 
Δ9THC vs. placebo- muscle 
spasticity  (Ashworth Scale) 
0.94 -0.44 to 2.31 
 
DISCUSSION  
Medical cannabis is legal in over 50% of the United States and is currently used by 
patients who suffer from muscle spasms, severe pain, glaucoma, seizures, headaches, cancer, 
HIV/AIDS, and Chron’s disease.10 Since cannabis is classified as a Schedule I substance, health 
insurance companies will not help pay for the medication. Therefore, patients suffering from 
debilitating diseases are forced to pay the full price.11 Research has resulted in the production of 
three synthetic cannabinoid products: dronabinol, nabilone, and epidiolex. Epidiolex was 
recently FDA-approved in June 2018 to treat Lennox-Gastaut syndrome and Dravet syndrome in 
patients 2 years or older.10 Cannabis and synthetic cannabinoids are contraindicated in patients 
  
with previous history of hypersensitivity reactions to medications, hepatic disease, 
cardiovascular disease, women who are pregnant, history of substance abuse, and 
coadministration with other CNS depressant medications.10  
The three RCTs discussed in this review show statistical evidence that cannabinoids, 
whether smoked or taken orally, are efficacious in reducing muscle spasticity and body pain for 
patients with MS. Although one study did not show clinically significant improvement of 
spasticity when assessed by the Ashworth scale9, subjective patient-oriented rating scales 
consistently showed reductions in spasticity and body pain across all three studies. Future studies 
would benefit by evaluating efficacy of this treatment method in elderly patients greater than 65 
years old. Due to the newly approved FDA drug, Epidiolex, clinical trials assessing a pediatric 
population is now warranted.   
 A notable limitation of each study discussed in this review is the ability to completely 
blind participants from psychoactive substances. Participants could often tell which treatment 
they were receiving. However, investigators noted that this limitation was unlikely to affect 
objective spasticity scores. A second limitation is the reliability of the Ashworth scale. This 
measurement tool was implemented for these clinical trials because it is the most widely used in 
clinical practice. However, it is too insensitive to identify small but clinically significant effects 
on spasticity. This may explain why the CAMS study failed to show clinically significant 
improvement in muscle spasticity when assessed by the Ashworth scale.  
 
CONCLUSION 
The evidence presented in this review is conflicting as to whether or not cannabis is an 
effective intervention for muscle spasticity and body pain. When measured via the Ashworth 
  
scale, the study conducted by Bloom et al.7 showed a mean reduction of 2.95 points compared to 
baseline scores. However, the CAMS study by Zajicek et al.9 did not show a clinically significant 
effect with either oral cannabis extract or Δ9THC as they both reduced spasticity scores by less 
than 1 point when compared to the placebo group. Data from the CRSs in each study consistently 
proved that patient’s perceived the treatment to be effective in reducing muscle spasticity and 
body pain.  
When conducting future research on this topic, slower dose-titration of the oral cannabis 
capsules need to be initiated. The MUSEC trial by Zajicek et al.8 titrated their oral cannabis 
treatment over two weeks. Similarly, the methods of the CAMS study involved a short 5-week 
titration period.9 This does not reflect normal clinical routine where dose titration can take a 
more gradual course and side effects can be minimized. Future studies should also explore the 
possibility of administering this treatment method via sublingual route. This would allow 
investigators to more effectively achieve desired blood concentrations of the drug and increase 
bioavailability, which may result in further reductions of muscle spasticity and body pain.  
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